Amer M. Zeidan

11.7k citations

407 papers · 5.6k indexed · 1 hit paper · h-index 40

Hematology top 0.1%
- Acute Myeloid Leukemia Research 305
- Chronic Myeloid Leukemia Treatments 62
- Hematopoietic Stem Cell Transplantation 37
Genetics top 0.5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment 105
- Hemoglobinopathies and Related Disorders 46
- Chronic Lymphocytic Leukemia Research 34
Oncology top 2%
Internal Medicine top 5%
Immunology top 5%
Public Health, Environmental and Occupational Health
- Acute Lymphoblastic Leukemia research 61
Molecular Biology
- Histone Deacetylase Inhibitors Research 47

Co-authors: Jan Philipp Bewersdorf Steven D. Gore Maximilian Stahl Rory M. Shallis Nikolai A. Podoltsev Rami S. Komrokji Amy J. Davidoff Rong Wang
Cited by: Hematology Genetics Oncology
Journals: The Lancet (1 paper)Journal of Clinical Oncology (24 papers)SHILAP Revista de lepidopterología (2 papers)
Partner nations: United States Germany France

In The Last Decade

Amer M. Zeidan

374 papers receiving 5.6k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Amer M. Zeidan

Since Specialization

Citations

This map shows the geographic impact of Amer M. Zeidan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Amer M. Zeidan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Amer M. Zeidan more than expected).

Fields of papers citing papers by Amer M. Zeidan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Amer M. Zeidan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Amer M. Zeidan. The network helps show where Amer M. Zeidan may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Amer M. Zeidan, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Amer M. Zeidan Line = papers co-authored together Amer M. Zeidan links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Efficacy, molecular and translational analysis of TP53-mutated HR-MDS with bexmarilimab and azacitidine: Updated results from the bexmab Phase 1/2 study Blood ·Amer M. Zeidan,Anthony S. Stein,Johanna Rimpiläinen,Marja Pyörälä,Timo Siitonen,Brian Ball,Mikko Myllymäki,Joshua F. Zeidner,Emma Searle,Ruth Witherall,Petri Bono,Aneel Nimba,Joab Williamson,Sofia Aakko,Maija Hollmén,Mika Kontro,Naval Daver	2025	1
2	Treatment Patterns and Real-World Outcomes of Molecular Subgroups in Patients With AML Receiving Frontline Venetoclax-Based Therapy JCO Oncology Practice ·Curtis A. Lachowiez,Anna Barcellos,Christina M. Zettler,Andrew J. Belli,Laura L. Fernandes,Eric Hansen,Ching‐Kun Wang,Henry F. Owusu,Amer M. Zeidan,Eytan M. Stein,Ronan Swords	2025	1
3	Toxicity and Efficacy of Isavuconazole Vs Voriconazole As Anti-Fungal Prophylaxis for Patients with Acute Myeloid Leukemia Blood ·Cameron J. Hunter,Jan Philipp Bewersdorf,Lourdes Mendez,Nikolai A. Podoltsev,Amer M. Zeidan,William Eighmy,Heidi Roeder,Maricar Malinis,Rory M. Shallis	2024	1
4	Integrated genetic, epigenetic, and immune landscape of TP53 mutant AML and higher risk MDS treated with azacitidine Therapeutic Advances in Hematology ·Amer M. Zeidan,Jan Philipp Bewersdorf,Vanessa Hasle,Rory M. Shallis,Ethan Thompson,Daniel L. Menezes,Shelonidta Rose,Isaac W. Boss,Stephanie Halene,Torsten Haferlach,Brian A. Fox	2024	8
5	Myelodysplastic Syndromes and Myelodysplastic Syndromes/Myeloproliferative Neoplasms: A Real-World Experience From a Developing Country JCO Global Oncology ·Abdalla Awidi,Marah Alzubi,Nada Odeh,Jawad Alrawabdeh,Muntaser Al Zyoud,Yazan Hamadneh,Hisham Bawa'neh,Ahmad Magableh,Alaa Al-Shorman,Feras Al-Fararjeh,Tariq N. Aladily,Amer M. Zeidan	2024	0
6	Differentiation syndrome associated with treatment with IDH2 inhibitor enasidenib: pooled analysis from clinical trials Blood Advances ·Pau Montesinos,Amir T. Fathi,Stéphane de Botton,Eytan M. Stein,Amer M. Zeidan,Yue Zhu,Thomas Prébet,Carlos E. Vigil,Iryna Bluemmert,Xin Yu,Courtney D. DiNardo	2024	7
7	Global Disparities in the Characteristics and Outcomes of Leukemia Clinical Trials: A Cross-Sectional Study of the ClinicalTrials.gov Database JCO Global Oncology ·Abdulrahman Alhajahjeh,Lara K. Rotter,Jessica M. Stempel,Alyssa Grimshaw,Jan Philipp Bewersdorf,Ondřej Bláha,Tariq Kewan,Nikolai A. Podoltsev,Rory M. Shallis,Lourdes Mendez,Maximilian Stahl,Amer M. Zeidan	2024	2
8	Efficacy and safety results from the COMMANDS trial: A phase 3 study evaluating luspatercept vs epoetin alfa in erythropoiesis-stimulating agent (ESA)-naive transfusion-dependent (TD) patients (pts) with lower-risk myelodysplastic syndromes (LR-MDS). Journal of Clinical Oncology ·Guillermo Garcia‐Manero,Uwe Platzbecker,Valeria Santini,Amer M. Zeidan,Pierre Fenaux,Rami S. Komrokji,Jake Shortt,David Valcárcel,Anna Jonášová,Sophie Dimicoli‐Salazar,Ing Soo Tiong,Chien‐Chin Lin,Jiahui Li,Sandra Kreitz,Veronika Pozharskaya,Jeevan K. Shetty,Andrius Degulys,Carlo Finelli,Thomas Cluzeau,Matteo Giovanni Della Porta	2023	0
9	Long-term utilization and benefit of luspatercept in transfusion-dependent, erythropoiesis-stimulating agent-refractory or -intolerant patients with lower-risk myelodysplastic syndromes with ring sideroblasts Leukemia ·Uwe Platzbecker,Valeria Santini,Rami S. Komrokji,Amer M. Zeidan,Guillermo Garcia‐Manero,Rena Buckstein,Dimana Miteva,Karen L. Keeperman,Natalia Holot,Jose Alberto Nadal,Yinzhi Lai,Sadanand Vodala,Barbara Rosettani,Ana Carolina Giuseppi,Aylin Yücel,Pierre Fenaux	2023	7
10	Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs) Clinical Lymphoma Myeloma & Leukemia ·Amer M. Zeidan,Elizabeth S. Mearns,Carmen D. Ng,Anuj Shah,Neil Lamarre,Archibong Yellow-Duke,Neda Alrawashdh,Baiyu Yang,Wei‐Han Cheng,Cat N. Bui,Anders Svensson	2023	2
11	Statin use, survival and incidence of thrombosis among older patients with polycythemia vera and essential thrombocythemia Cancer Medicine ·Nikolai A. Podoltsev,Rong Wang,Rory M. Shallis,Jessica M. Stempel,Mengyang Di,Natalia Neparidze,Amer M. Zeidan,Scott F. Huntington,Smith Giri,Sarah C. Hull,Steven D. Gore,Xiaomei Ma	2023	8
12	Safety and Efficacy of Maintenance Treatment Following Allogeneic Hematopoietic Cell Transplant in Acute Myeloid Leukemia and Myelodysplastic Syndrome - a Systematic Review and Meta-Analysis Blood ·Jan Philipp Bewersdorf,Martin S. Tallman,Christina Cho,Amer M. Zeidan,Maximilian Stahl	2020	5
13	Predictors of Tyrosine Kinase Inhibitor Use Among Older Patients with Chronic Myeloid Leukemia in the United States Blood ·Rong Wang,Rory M. Shallis,Jan Philipp Bewersdorf,Amer M. Zeidan,Scott F. Huntington,Xiaomei Ma,Nikolai A. Podoltsev	2020	10
14	A Phase Ib Study of Onvansertib, a Novel Oral PLK1 Inhibitor, in Combination Therapy for Patients with Relapsed or Refractory Acute Myeloid Leukemia Clinical Cancer Research ·Amer M. Zeidan,Maya Ridinger,Tara L. Lin,Pamela S. Becker,Gary J. Schiller,Prapti A. Patel,Alexander I. Spira,Michaela L. Tsai,Errin Samuëlsz,Sandra Silberman,Mark G. Erlander,Eunice S. Wang	2020	57
15	Practice Patterns and Real-Life Outcomes for Patients with Acute Promyelocytic Leukemia Blood ·Jan Philipp Bewersdorf,Stephanie Prozora,Rong Wang,Nikolai A. Podoltsev,Rory M. Shallis,Scott F. Huntington,Natalia Neparidze,Xiaomei Ma,Steven D. Gore,Amer M. Zeidan,Amy J. Davidoff	2020	1
16	Patterns of care and clinical outcomes with cytarabine-anthracycline induction chemotherapy for AML patients in the United States Blood Advances ·Amer M. Zeidan,Nikolai A. Podoltsev,Xiaoyi Wang,Chi Zhang,Jan Philipp Bewersdorf,Rory M. Shallis,Scott F. Huntington,Natalia Neparidze,Smith Giri,Steven D. Gore,Amy J. Davidoff,Xiaomei Ma,Rong Wang	2020	38
17	Clinical Activity of CC-90009, a Cereblon E3 Ligase Modulator and First-in-Class GSPT1 Degrader, As a Single Agent in Patients with Relapsed or Refractory Acute Myeloid Leukemia (R/R AML): First Results from a Phase I Dose-Finding Study Blood ·Geoffrey L. Uy,Mark D. Minden,Pau Montesinos,Daniel J. DeAngelo,Jessica K. Altman,Jamie Koprivnikar,Paresh Vyas,Yngvar Fløisand,María‐Belén Vídriales,Bjørn Tore Gjertsen,Jordi Esteve,Tonia J. Buchholz,Suzana S. Couto,Jinhong Fan,Bishoy Hanna,Li Li,Daniel W. Pierce,Kristen Hege,Michael Pourdehnad,Amer M. Zeidan	2019	23
18	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure Clinical Cancer Research ·Amer M. Zeidan,Hanna A. Knaus,Tara M. Robinson,Andrea Towlerton,Edus H. Warren,Joshua F. Zeidner,Amanda L. Blackford,Amy S. Duffield,David A. Rizzieri,Mark G. Frattini,Yair Levy,Mark A. Schroeder,Anna Ferguson,Katherine E. Sheldon,Amy E. DeZern,Ivana Gojo,Steven D. Gore,Howard Streicher,Leo Luznik,B. Douglas Smith	2018	74
19	Comparing the prognostic value of risk stratifying models for patients with lower‐risk myelodysplastic syndromes: Is one model better? American Journal of Hematology ·Amer M. Zeidan,Mikkael A. Sekeres,Xiaofeng Wang,Najla Al Ali,Guillermo Garcia‐Manero,David P. Steensma,Gail J. Roboz,John Barnard,Eric Padron,Amy E. DeZern,Jaroslaw P. Maciejewski,Alan F. List,Rami S. Komrokji	2015	23
20	Comparing the Prognostic Value of Risk stratifying Models for Patients with Lower-Risk Myelodysplastic Syndromes: Is one model better? American Journal of Hematology ·Amer M. Zeidan,Mikkael A. Sekeres,Xiaofeng Wang,Najla Al Ali,Guillermo Garcia‐Manero,David P. Steensma,Gail J. Roboz,John Barnard,Eric Padron,Amy E. DeZern,Jaroslaw P. Maciejewski,Alan F. List,Rami S. Komrokji	2015	2

About Amer M. Zeidan

Amer M. Zeidan is a scholar working on Hematology, Genetics and Oncology, having authored 407 papers that have together received 5.6k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (305 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (105 papers), Chronic Myeloid Leukemia Treatments (62 papers), Acute Lymphoblastic Leukemia research (61 papers), Histone Deacetylase Inhibitors Research (47 papers), Hemoglobinopathies and Related Disorders (46 papers), Hematopoietic Stem Cell Transplantation (37 papers) and Chronic Lymphocytic Leukemia Research (34 papers). The work is most often cited by research in Hematology (3.7k citations), Genetics (1.4k citations) and Oncology (1.3k citations). Amer M. Zeidan has collaborated with scholars based in United States, Germany and France. Frequent co-authors include Jan Philipp Bewersdorf, Steven D. Gore, Maximilian Stahl, Rory M. Shallis, Nikolai A. Podoltsev, Rami S. Komrokji, Amy J. Davidoff, Rong Wang, Xiaomei Ma and Scott F. Huntington. Their work appears in journals such as The Lancet, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact